Cargando…

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme

BACKGROUND: Mepolizumab was available in France as part of an early access programme for patients with severe eosinophilic asthma (nominative autorisation temporaire d'utilisation [temporary use authorisation] (nATU)) before its commercialisation. This study aimed to characterise patients who r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taillé, Camille, Chanez, Pascal, Devouassoux, Gilles, Didier, Alain, Pison, Christophe, Garcia, Gilles, Charriot, Jeremy, Bouée, Stéphane, Gruber, Alina, Pribil, Celine, Bourdin, Arnaud, Humbert, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315004/ https://www.ncbi.nlm.nih.gov/pubmed/32241829 http://dx.doi.org/10.1183/13993003.02345-2019

Ejemplares similares

Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study
por: Mattei, Laura, et al.
Publicado: (2021)

How can we minimise the use of regular oral corticosteroids in asthma?
por: Bourdin, Arnaud, et al.
Publicado: (2020)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies
por: Casale, Thomas B., et al.
Publicado: (2022)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
por: Ueno, Masanobu, et al.
Publicado: (2021)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
por: Liu, Mark C., et al.
Publicado: (2021)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study
por: Suehs, Carey Meredith, et al.
Publicado: (2020)

From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
por: Pavord, Ian D., et al.
Publicado: (2021)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database
por: Taha, Muhamed-Kheir, et al.
Publicado: (2021)

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET
por: Liu, Mark C., et al.
Publicado: (2022)

Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab
por: Herout, Sandra, et al.
Publicado: (2018)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
por: Long, Gabriella, et al.
Publicado: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
por: Mkorombindo, Takudzwa, et al.
Publicado: (2019)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
por: Otoshi, Ryota, et al.
Publicado: (2019)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
por: Albers, Frank C., et al.
Publicado: (2019)

Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database
por: Weil-Olivier, Catherine, et al.
Publicado: (2022)

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)
por: Moore, Wendy C., et al.
Publicado: (2022)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
por: Condreay, Lynn D., et al.
Publicado: (2020)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis
por: Wang, Chrong-Reen, et al.
Publicado: (2022)

Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia
por: Daboussi, Selsabil, et al.
Publicado: (2023)

Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement
por: Afiari, Agura, et al.
Publicado: (2020)

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance
por: Kisling, Adam, et al.
Publicado: (2020)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
por: Pavord, Ian D., et al.
Publicado: (2022)

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
por: Bettiol, Alessandra, et al.
Publicado: (2021)

Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report
por: Toscano Peña, Andrés, et al.
Publicado: (2023)

Epithelial ciliated beating cells essential for ex vivo ALI culture growth
por: Gras, Delphine, et al.
Publicado: (2017)

Association between increased mortality and bronchial fibroscopy in intensive care units and intermediate care units during COPD exacerbations: an analysis of the 2014 and 2015 National French Medical-based Information System Databases (PMSI)
por: Amalric, Matthieu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aefs907i25r52brk77m51hodg2